Open AccessThe Impact of First-Line Anti-Tubercular Drugs’ Pharmacokinetics on Treatment Outcome: A Systematic Review
Author(s) -
Tesemma Sileshi,
Esayas Tadesse,
Eyasu Makonnen,
Eleni Aklillu
Publication year - 2021
Publication title -
clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.685
H-Index - 27
ISSN - 1179-1438
DOI - 10.2147/cpaa.s289714
Subject(s) - pyrazinamide , medicine , pharmacokinetics , rifampicin , tuberculosis , isoniazid , observational study , cochrane library , meta analysis , drug , ethambutol , first line , medline , pharmacology , intensive care medicine , pathology , political science , law
Tuberculosis remains the major public health problem besides tremendous efforts to combat it. Most tuberculosis patients are treated with a standard dose of first-line anti-TB drugs. The cure rate, however, varies from patient to patient. Various factors have been related to anti-TB treatment failure. In recent years, studies associating lower plasma concentrations of anti-TB drugs with poor treatment outcomes are emerging although the results are inconclusive.